AZD-5004
- Generic Name
- AZD-5004
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT06948747
- Locations
- πΊπΈ
Research Site, Brooklyn, Maryland, United States
A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants
Phase 1
Not yet recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT06942936
- Locations
- π©πͺ
Research Site, Berlin, Germany
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT06813781
- Locations
- πΊπΈ
Research Site, San Antonio, Texas, United States
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT06742762
- Locations
- πΊπΈ
Research Site, Orlando, Florida, United States
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 310
- Registration Number
- NCT06579092
- Locations
- π¬π§
Research Site, Witney, United Kingdom
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Phase 2
Recruiting
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 384
- Registration Number
- NCT06579105
- Locations
- π¬π§
Research Site, Yate, United Kingdom
A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT06555822
- Locations
- πΊπΈ
Research Site, Brooklyn, Maryland, United States
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eccogene
- Target Recruit Count
- 48
- Registration Number
- NCT06293742
- Locations
- πΊπΈ
Eccogene Investigational Site, Anaheim, California, United States
ECC5004 RBA FE Study in Healthy Participants
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Eccogene
- Target Recruit Count
- 14
- Registration Number
- NCT06268145
- Locations
- πΊπΈ
Eccogene Investigational Site, Anaheim, California, United States
FTIH of ECC5004 in Healthy and Diabetic Participants
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Eccogene
- Target Recruit Count
- 69
- Registration Number
- NCT05654831
- Locations
- πΊπΈ
Eccogene Investigational Site, Anaheim, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath